1stOncology™: Cancer Intelligence Service – Page 14078 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Anixa Biosciences Presents Cchek™ Prostate Cancer Detection Data at AACR Annual Meeting

On April 3, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported the latest data from its ongoing study on prostate cancer detection, utilizing Cchek, its artificial intelligence (AI) driven cancer detection technology, at the 2019 annual meeting of the American Association of Cancer Research (AACR) (Free AACR Whitepaper) (Press release, Anixa Biosciences, APR 3, 2019, View Source [SID1234534984]). The meeting was held March 29–April 3, 2019 and was attended by world leading experts across the field of cancer research. Anixa’s presentation is available on the Company’s website, at: www.anixa.com/cchek/recent-data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Dr. Amit Kumar, CEO of Anixa, stated, "We are pleased with the response received on our presentation from the scientific community, and look forward to the impact our technology may have on cancer treatment."

Checkpoint Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

On April 3, 2019 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, reported that James F. Oliviero, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019, at 2:40 p.m. GMT (Press release, Checkpoint Therapeutics, APR 3, 2019, View Source [SID1234534983]). The conference will be held at the Grosvenor House Hotel in London, UK.

A live webcast of the presentation will be available on the Events page of the Investors & Media section of Checkpoint’s website: www.checkpointtx.com.

Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

On April 3, 2019 Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory, cancer and other diseases, reported that Allan Reine, Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. will present at the 2019 H.C. Wainwright Global Life Sciences Conference in London, U.K. on Monday, April 8, 2019 at 1:30 PM (GMT) (Press release, Pieris Pharmaceuticals, APR 3, 2019, View Source [SID1234534981]). A webcast of the company’s presentation will be available at this link.

AVEO Pharmaceuticals, Inc. Announces Pricing of $25 Million Underwritten Public Offering

On April 3, 2019 AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) ("AVEO" or the "Company"), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, reported the pricing of its previously announced underwritten public offering of 21,739,131 shares of common stock and short-term warrants to purchase up to 21,739,131 shares of common stock at a price to the public of $1.15 per share and accompanying warrant (Press release, AVEO, APR 3, 2019, View Source [SID1234534975]). The Company expects to receive gross proceeds of approximately $25 million from the offering. The offering is expected to close on or about April 8, 2019, subject to customary closing conditions.

H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

Each warrant has an exercise price of $1.25 per share of common stock, will be immediately exercisable upon issuance, and will expire on the second anniversary of the date of issuance.

The Company has granted the underwriters a 30-day option to purchase up to 3,260,869 additional shares of common stock and/or warrants to purchase 3,260,869 shares of common stock at the public offering price, less underwriting discounts and commissions.

The Company intends to use the net proceeds from the offering for ongoing clinical and preclinical development of its product candidates, as well as for working capital and other general corporate purposes.

The securities described above were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-221837) previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on December 15, 2017. A preliminary prospectus supplement and an accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, or by calling (646) 975-6996 or by emailing [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering

On April 3, 2019 AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) ("AVEO" or the "Company"), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, reported it has commenced an underwritten public offering of its shares of common stock, together with warrants to purchase shares of common stock (Press release, AVEO, APR 3, 2019, View Source [SID1234534974]). The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants to be sold in the offering at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

The securities described above are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-221837) previously filed with and declared effective by the Securities and Exchange Commission ("SEC") on December 15, 2017. A preliminary prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, or by calling (646) 975-6996 or by emailing [email protected].

Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus to be filed with the SEC, and the other documents that the Company has filed with the SEC that will be incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which will provide more information about the Company and the offering.